Search Results

N Latex FLC kappa and lambda assays: In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda, in human serum and EDTA plasma by means of particle-enhanced immunonephelometry using the BN Systems. FLC measurements are used as an aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL).
N FLC Supplementary Reagent: Supplementary reagent for the immunonephelometric determination of free light chains (FLC), type kappa and type lambda on BN Systems. A mixture of both supplementary reagents is used to suppress interference by rheumatoid factors and human anti-mouse antibodies (HAMA).
N FLC Standard SL: Establishment of reference curves for the determination of free light chains (FLC), type kappa and type lambda on the BN Systems.
N FLC Controls SL1 and SL2: The N FLC Controls SL1 and SL2 are for use as assayed accuracy controls in the determination of free light chains (FLC), type kappa and type lambda by immunonephelometry with the BN Systems.

Device Description

The N Latex FLC (free light chain) assays are in vitro diagnostic reagents for the quantitative determination of free light chains, type kappa or type lambda, in human serum and EDTA plasma by means of particle-enhanced immunonephelometry using the BN™ II and BN ProSpec® Systems. Used in conjunction with other clinical and laboratory findings, FLC measurements are used as an aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL). Used in conjunction with the assay reagents, N FLC Standard SL is for use in the establishment of reference curves for the determination of free light chains, type kappa and type lambda on the BN™ II and BN ProSpec® Systems. The N FLC Control SL 1 and 2 products are for use as assayed accuracy controls and precision controls in the determination of free light chains, type kappa and type lambda by immunonephelometry with the BN™ II and BN ProSpec® Systems. The FLC test systems are based upon the principles of particle-enhanced immunonephelometry. Polystyrene particles coated with monoclonal antibodies to human free light chains, type kappa or lambda, respectively, are agglutinated when mixed with samples containing FLC. These aggregates scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

AI/ML Overview

The provided text describes the Siemens N Latex FLC kappa and N Latex FLC lambda assays, along with their associated calibrators and controls. These devices are intended for the quantitative determination of free light chains (FLC) in human serum and EDTA plasma, used as an aid in diagnosing multiple myeloma (MM) and amyloidosis (AL).

Here's an analysis of the acceptance criteria and the study that proves the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are generally implied by the performance characteristics presented in the study. For analytical performance, typical acceptance limits for precision (CV%), linearity, and interference are industry standards for IVD devices. For clinical performance, the reported sensitivity and specificity values against clinical diagnosis are the acceptance metrics.

Acceptance Criteria Category	Specific Metric	Acceptance Criteria (Implied/Standard)	Reported Device Performance and Remarks
Analytical Performance	Precision (Total CV%)	Typically < 10-15% for clinical assays, varying by analyte concentration. CLSI EP05-A3 guidelines were followed.	FN II Instrument:- Kappa: Total CV% ranges from 3.45% (S1, 11.43 mg/L) to 4.55% (C1, 14.60 mg/L) to 3.81% (S3, 81.31 mg/L). Max 4.55%.- Lambda: Total CV% ranges from 5.60% (S1, 10.91 mg/L) to 6.61% (S2, 27.84 mg/L) to 6.89% (S3, 44.46 mg/L). Max 6.89%.BN ProSpec Instrument:- Kappa: Total CV% ranges from 5.24% (S1, 11.03 mg/L) to 5.58% (C2, 36.33 mg/L) to 7.68% (S3, 79.04 mg/L). Max 7.68%.- Lambda: Total CV% ranges from 3.22% (C1, 13.82 mg/L) to 4.71% (S3, 44.69 mg/L) to 4.28% (S1, 10.87 mg/L). Max 4.71%.Lot-to-Lot (BN II):- Kappa: Total CV% ranges from 4.00% (S2, 25.91 mg/L) to 6.35% (S1, 11.66 mg/L) to 5.58% (C2, 37.40 mg/L). Max 6.35%.- Lambda: Total CV% ranges from 6.19% (S2, 26.35 mg/L) to 9.44% (S3, 41.59 mg/L) to 8.54% (S1, 10.30 mg/L). Max 9.44%.Lot-to-Lot (BN ProSpec):- Kappa: Total CV% ranges from 5.23% (S2, 26.15 mg/L) to 7.87% (S1, 11.18 mg/L) to 7.39% (S3, 81.79 mg/L). Max 7.87%.- Lambda: Total CV% ranges from 4.47% (S2, 27.24 mg/L) to 7.97% (S1, 10.79 mg/L) to 7.59% (S3, 44.11 mg/L). Max 7.97%.All precision values are well within acceptable clinical laboratory ranges.
	Measuring Range (Linearity)	Assays should be linear across their claimed measuring range. CLSI EP06-A guidelines were followed.	Kappa: Claimed 3.4 to 110 mg/L. Supported by linearity studies.Lambda: Claimed 1.9 to 60 mg/L. Supported by linearity studies.
	Limit of Quantitation (LoQ)	LoQ should demonstrate analytical performance (e.g., total error) at low concentrations. CLSI EP17-A2 guidelines were followed.	Kappa: 0.195 mg/L with a total error of 10.57%.Lambda: 0.532 mg/L with a total error of 10.01%. These values indicate acceptable performance at the lower end of the measuring range.
	High Dose Hook Effect (Antigen Excess)	No hook effect (false negatives) should be observed at high concentrations.	No hook effect observed up to 27,100 mg/L for FLC kappa and 57,300 mg/L for FLC lambda due to built-in pre-reaction protocols on BN II and BN ProSpec. Meets criteria.
	Specificity (Interference)	No significant interference from common endogenous and exogenous substances at specified concentrations. CLSI EP7-A2 guidelines were followed.	A variety of substances (e.g., Acetamidophenol, Heparin, Triglycerides, Hemoglobin, Bilirubin, RF, etc.) showed no interference up to high specified concentrations. Meets criteria.
Clinical Performance	Sensitivity for Multiple Myeloma (MM)	High sensitivity is crucial for diagnostic aid.	95.8 % (95 % Confidence Interval: 89.8 to 98.4 %). Very good sensitivity.
	Specificity for Multiple Myeloma (MM)	High specificity is crucial for diagnostic aid.	96.9 % (95 % Confidence Interval: 93.0 to 98.7 %). Very good specificity.
	Sensitivity for AL Amyloidosis (AL)	High sensitivity is crucial for diagnostic aid.	83.1 % (95 % Confidence Interval: 73.7 to 89.7 %). Good sensitivity.
	Specificity for AL Amyloidosis (AL)	High specificity is crucial for diagnostic aid.	96.9 % (95 % Confidence Interval: 93.0 to 98.7 %). Very good specificity. (Note: Specificity is the same as for MM, indicating the same non-diseased control group was used for both calculations).
Method Comparison	Agreement Rate vs. Predicate Device for FLC kappa	High agreement rate is expected for substantial equivalence.	Overall agreement rate: (Value is missing from the table; it only shows the counts for each category. Based on the provided numbers, it's 102+23+6+11+3+1 / 152 = 146/152 = 96.05% agreement for Kappa based on the comparison method's categories, and 102/152 = 67.1% in the high range, 23/152 = 15.1% in the normal range, 6/152 = 3.9% in the low range. The table entries are counts in overlapping categories relative to the predicate's reference intervals, not a direct agreement percentage. The provided table does not explicitly state the "overall agreement rate" but shows cell counts, implying successful comparison.)
	Agreement Rate vs. Predicate Device for FLC lambda	High agreement rate is expected for substantial equivalence.	Overall agreement rate: (Value is missing in the table, similar to kappa. Based on the provided numbers, it's 85+23+2+10+6+16 / 152 = 142/152 = 93.42% agreement for Lambda based on the comparison method's categories. The provided table does not explicitly state the "overall agreement rate".)

2. Sample Size Used for the Test Set and Data Provenance

Precision and Reproducibility:
- Sample Size: Serum samples were obtained from commercial sources. Three levels of serum specimens (S1-S3) and two levels of controls (C1, C2) were used. The exact number of individual patient samples aggregated into these pools is not specified, but the testing involved multiple replicates, runs, two instruments across three lots of reagents, suggesting extensive measurements.
- Data Provenance: Not explicitly stated, but likely from a laboratory setting. No indication of retrospective/prospective or country of origin for these pooled specimens.
Measuring Range (Linearity and LoQ):
- Sample Size: A test specimen for linearity was diluted to 9 levels. Serum and EDTA plasma specimens from four healthy donors from Sanquin Blood Bank (one donor each for kappa EDTA plasma and serum and one donor each for lambda EDTA plasma and serum) were used.
- For LoQ, five individual serum samples with very low concentrations of FLC kappa and five for FLC lambda were used.
- Data Provenance: Fresh human serum and EDTA plasma. Sanquin Blood Bank is a Dutch organization, suggesting the data provenance is European (Netherlands).
High Dose Hook Effect:
- Sample Size: Serum samples with high concentrations of FLC kappa and FLC lambda were used. The number of samples is not specified.
- Data Provenance: Not specified.
Specificity (Interference):
- Sample Size: Not explicitly stated how many samples or replicates were used for each interferent, but the study implies testing against various concentrations for each listed substance.
- Data Provenance: Not specified.
Expected Values / Reference Interval:
- Sample Size: 201 apparently healthy subjects.
- Data Provenance: US-population. This was a prospective study to establish reference intervals.
Clinical Sensitivity and Specificity:
- Sample Size: A total of 342 samples. This included:
  - 96 samples from Multiple Myeloma patients.
  - 83 samples from AL Amyloidosis patients.
  - 163 samples from non-myeloma patients with various clinical conditions (24 polyclonal immunoglobulin stimulation, 16 Chronic Kidney Disease (CKD), and 123 other clinical conditions).
- Data Provenance: Not explicitly stated, but these are patient samples. The type of study (retrospective/prospective) is not mentioned for this section, but it's common for such validation sets to be carefully curated retrospective collections.
Method Comparison with Predicate Device:
- Sample Size: 152 serum samples from patients with monoclonal gammopathy.
- Data Provenance: Patients with monoclonal gammopathy. Not specified if retrospective or prospective or country of origin.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish the "ground truth" for the test set in the conventional sense of a diagnostic imaging or pathology study.

For the clinical sensitivity and specificity study: The "ground truth" was established by "Clinical Diagnosis of Multiple Myeloma" and "Clinical Diagnosis of Amyloidosis." This implies diagnosis made by clinicians based on established diagnostic criteria, which would involve multiple medical professionals (e.g., oncologists, hematologists, nephrologists, pathologists) but these are not explicitly qualified or counted in this document.
For analytical studies (precision, linearity, LoQ, interference): The "ground truth" is typically defined by the known concentrations or characteristics of the reagents/samples used and verified by established analytical methods, not by human expert opinion.

4. Adjudication Method for the Test Set

Not applicable for this type of in-vitro diagnostic device study. Adjudication methods like 2+1 or 3+1 are typically used in imaging studies where multiple readers interpret images, and a consensus or majority vote establishes ground truth. In this case, "ground truth" for the clinical study is based on a clinical diagnosis, which is a broader process.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was Done

No, an MRMC comparative effectiveness study was not done. This type of study is relevant for comparing human reader performance with and without AI assistance, typically in medical imaging. The N Latex FLC assays are IVD assays that provide quantitative measurements, not interpretations by human readers that would be augmented by AI.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was Done

Yes, the studies described are for the standalone performance of the N Latex FLC assays. These are automated laboratory tests where the device (the assay and instrument system) performs the measurement and outputs a quantitative result. There isn't a "human-in-the-loop" for the interpretation of the raw signal data, though a clinician then interprets the numerical FLC results in the context of other clinical findings. The performance metrics (precision, linearity, LoQ, sensitivity, specificity) reflect the algorithm/device's performance directly.

7. The Type of Ground Truth Used

Clinical Sensitivity and Specificity: "Clinical Diagnosis of Multiple Myeloma" and "Clinical Diagnosis of Amyloidosis." This would typically be based on a combination of clinical signs, symptoms, other laboratory tests, bone marrow biopsy results, and imaging studies, as per established medical guidelines.
Analytical Studies (Precision, Linearity, LoQ, Hook Effect, Interference): Ground truth was established by known concentrations of analytes in prepared samples or by the absence/presence of interfering substances at specified levels. For example, linearity samples were prepared by serial dilution from a high concentration, and LoQ samples were prepared to known very low concentrations. For interference, substances were added at specific concentrations.
Reference Intervals: Based on measurements from an "apparently healthy subject" population (201 subjects from a US-population).

8. The Sample Size for the Training Set

The document does not explicitly mention a "training set" in the context of an AI/ML algorithm. This device is an immunoassay using a well-established technology (particle-enhanced immunonephelometry). Such systems are typically developed and validated using calibration and verification samples, but not "training sets" in the machine learning sense. The N FLC Standard SL is used for establishing reference curves (calibration), which is a form of "training" for quantitative measurement but not for a high-level diagnostic algorithm that learns from data.

9. How the Ground Truth for the Training Set Was Established

As noted above, a "training set" in the AI/ML context is not directly applicable here.

For the calibration (N FLC Standard SL): "Calibration of the assay is traceable to an internal master calibrator." This master calibrator's "ground truth" (assigned value) would have been established through a rigorous internal development and characterization process, likely involving primary reference materials or highly characterized analytical methods, though the specific details are not provided in this summary.
For the controls (N FLC Control SL1 and SL2): "The concentration of the free light chains (FLC), type kappa and type lambda is calibrated against standard preparations and is lot-dependent." This means their "ground truth" values are assigned relative to the calibration curve established using the N FLC Standard SL, which in turn refers to the internal master calibrator.

Ask a Question

Ask a specific question about this device

Page 1 of 1